VYXARIQ

Serial Number 98787901
688

Registration Progress

Application Filed
Oct 7, 2024
Under Examination
Jun 10, 2025
Approved for Publication
Apr 15, 2025
Published for Opposition
Apr 15, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Dec 10, 2025 45 days

Trademark Image

VYXARIQ

Basic Information

Serial Number
98787901
Filing Date
October 7, 2024
Published for Opposition
April 15, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
Jun 10, 2025
Application
Pending
Classes
005

Rights Holder

Applied Therapeutics, Inc.

03
Address
545 Fifth Avenue, Suite 1400
New York, NY 10017

Ownership History

Applied Therapeutics, Inc.

Original Applicant
03
New York, NY

Applied Therapeutics, Inc.

Owner at Publication
03
New York, NY

Legal Representation

Attorney
Anna Kurian Shaw

USPTO Deadlines

Next Deadline
45 days remaining
NOA E-Mailed - SOU Required
Due Date
December 10, 2025
Extension Available
Until June 10, 2026

Application History

8 events
Date Code Type Description Documents
Jun 10, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 15, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 15, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 9, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 20, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 20, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 7, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 7, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for treatment of diabetes complications; Pharmaceutical preparations for treatment of heart diseases or disorders, eye diseases or disorders, nervous system diseases or disorders, kidney diseases or disorders, cardiomyopathy, neuropathy, retinopathy, and nephropathy; Pharmaceutical preparations for inhibiting aldose reductase

Classification

International Classes
005